The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Authors: Abraham, J.E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L.M., Lucey, R., Fulton, A., Roberts, A.N., Worley, J.R., Chhabra, A., Qian, W., Vallier, A.L., Hardy, R.M., Chan, S., Hickish, T., Tripathi, D., Venkitaraman, R., Persic, M., Aslam, S., Glassman, D., Raj, S., Borley, A., Braybrooke, J.P., Sutherland, S., Staples, E., Scott, L.C., Davies, M., Palmer, C.A., Moody, M., Churn, M.J., Newby, J.C., Mukesh, M.B., Chakrabarti, A., Roylance, R.R., Schouten, P.C., Levitt, N.C., McAdam, K., Armstrong, A.C., Copson, E.R., McMurtry, E., Tischkowitz, M., Provenzano, E., Earl, H.M.
Journal: Nature
Publication Date: 30/05/2024
Volume: 629
Issue: 8014
Pages: 1142-1148
eISSN: 1476-4687
ISSN: 0028-0836
DOI: 10.1038/s41586-024-07384-2
Abstract:PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer1,2, who were germline BRCA1 and BRCA2 wild type3. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin–paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)4, and secondary end points included event-free survival (EFS) and overall survival (OS)5. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (P = 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank P > 0.9), respectively; OS was 90% and 87.2% (log-rank P = 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank P < 0.001), and OS was 96% and 83% (log-rank P < 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin–paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline BRCA1 and BRCA2 wild type. ClinicalTrials.gov ID: NCT03150576.
Source: Scopus
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
Authors: Abraham, J.E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L.M., Lucey, R., Fulton, A., Roberts, A.N., Worley, J.R., Chhabra, A., Qian, W., Vallier, A.-L., Hardy, R.M., Chan, S., Hickish, T., Tripathi, D., Venkitaraman, R., Persic, M., Aslam, S., Glassman, D., Raj, S., Borley, A., Braybrooke, J.P., Sutherland, S., Staples, E., Scott, L.C., Davies, M., Palmer, C.A., Moody, M., Churn, M.J., Newby, J.C., Mukesh, M.B., Chakrabarti, A., Roylance, R.R., Schouten, P.C., Levitt, N.C., McAdam, K., Armstrong, A.C., Copson, E.R., McMurtry, E., Tischkowitz, M., Provenzano, E., Earl, H.M.
Journal: Nature
Publication Date: 05/2024
Volume: 629
Issue: 8014
Pages: 1142-1148
eISSN: 1476-4687
DOI: 10.1038/s41586-024-07384-2
Abstract:PARTNER is a prospective, phase II-III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer1,2, who were germline BRCA1 and BRCA2 wild type3. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin-paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)4, and secondary end points included event-free survival (EFS) and overall survival (OS)5. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (P = 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank P > 0.9), respectively; OS was 90% and 87.2% (log-rank P = 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank P < 0.001), and OS was 96% and 83% (log-rank P < 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin-paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline BRCA1 and BRCA2 wild type. ClinicalTrials.gov ID: NCT03150576 .
Source: PubMed
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Authors: Abraham, J.E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L.M., Lucey, R., Fulton, A., Roberts, A.N., Worley, J.R., Chhabra, A., Qian, W., Vallier, A.-L., Hardy, R.M., Chan, S., Hickish, T., Tripathi, D., Venkitaraman, R., Persic, M., Aslam, S., Glassman, D., Raj, S., Borley, A., Braybrooke, J.P., Sutherland, S., Staples, E., Scott, L.C., Davies, M., Palmer, C.A., Moody, M., Churn, M.J., Newby, J.C., Mukesh, M.B., Chakrabarti, A., Roylance, R.R., Schouten, P.C., Levitt, N.C., Mcadam, K., Armstrong, A.C., Copson, E.R., Mcmurtry, E., Tischkowitz, M., Provenzano, E., Earl, H.M.
Journal: NATURE
Publication Date: 30/05/2024
Volume: 629
Issue: 8014
eISSN: 1476-4687
ISSN: 0028-0836
DOI: 10.1038/s41586-024-07384-2
Source: Web of Science
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
Authors: Abraham, J.E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L.M., Lucey, R., Fulton, A., Roberts, A.N., Worley, J.R., Chhabra, A., Qian, W., Vallier, A.-L., Hardy, R.M., Chan, S., Hickish, T., Tripathi, D., Venkitaraman, R., Persic, M., Aslam, S., Glassman, D., Raj, S., Borley, A., Braybrooke, J.P., Sutherland, S., Staples, E., Scott, L.C., Davies, M., Palmer, C.A., Moody, M., Churn, M.J., Newby, J.C., Mukesh, M.B., Chakrabarti, A., Roylance, R.R., Schouten, P.C., Levitt, N.C., McAdam, K., Armstrong, A.C., Copson, E.R., McMurtry, E., Tischkowitz, M., Provenzano, E., Earl, H.M.
Journal: Nature
Publication Date: 05/2024
Volume: 629
Issue: 8014
Pages: 1142-1148
eISSN: 1476-4687
ISSN: 0028-0836
DOI: 10.1038/s41586-024-07384-2
Abstract:PARTNER is a prospective, phase II-III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer1,2, who were germline BRCA1 and BRCA2 wild type3. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin-paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)4, and secondary end points included event-free survival (EFS) and overall survival (OS)5. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (P = 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank P > 0.9), respectively; OS was 90% and 87.2% (log-rank P = 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank P < 0.001), and OS was 96% and 83% (log-rank P < 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin-paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline BRCA1 and BRCA2 wild type. ClinicalTrials.gov ID: NCT03150576 .
Source: Europe PubMed Central